CO2023006516A2 - Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de la neuropatía provocada por o acompañada de la enfermedad de fabry - Google Patents
Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de la neuropatía provocada por o acompañada de la enfermedad de fabryInfo
- Publication number
- CO2023006516A2 CO2023006516A2 CONC2023/0006516A CO2023006516A CO2023006516A2 CO 2023006516 A2 CO2023006516 A2 CO 2023006516A2 CO 2023006516 A CO2023006516 A CO 2023006516A CO 2023006516 A2 CO2023006516 A2 CO 2023006516A2
- Authority
- CO
- Colombia
- Prior art keywords
- prevention
- fusion protein
- accompanied
- treatment
- fabry disease
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 201000001119 neuropathy Diseases 0.000 title abstract 2
- 230000007823 neuropathy Effects 0.000 title abstract 2
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000024720 Fabry Disease Diseases 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200152246 | 2020-11-13 | ||
| PCT/KR2021/016629 WO2022103220A1 (ko) | 2020-11-13 | 2021-11-15 | 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023006516A2 true CO2023006516A2 (es) | 2023-06-09 |
Family
ID=81601490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0006516A CO2023006516A2 (es) | 2020-11-13 | 2023-05-17 | Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de la neuropatía provocada por o acompañada de la enfermedad de fabry |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230416714A1 (enExample) |
| EP (1) | EP4245310A4 (enExample) |
| JP (1) | JP2023549322A (enExample) |
| KR (1) | KR20220065720A (enExample) |
| CN (1) | CN116419759A (enExample) |
| AU (1) | AU2021377712A1 (enExample) |
| CA (1) | CA3196264A1 (enExample) |
| CO (1) | CO2023006516A2 (enExample) |
| IL (1) | IL302857A (enExample) |
| MX (1) | MX2023005579A (enExample) |
| WO (1) | WO2022103220A1 (enExample) |
| ZA (1) | ZA202304536B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230134823A (ko) * | 2022-03-15 | 2023-09-22 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| CA3048151A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| EP3650539A4 (en) * | 2017-07-07 | 2021-08-18 | Hanmi Pharm. Co., Ltd. | NEW THERAPEUTIC ENZYMFUSION PROTEIN AND ITS USAGE |
| BR112020012346A2 (pt) * | 2017-12-22 | 2020-11-24 | Hanmi Pharm. Co., Ltd. | proteína de fusão enzimática terapêutica tendo uma nova estrutura e uso da mesma |
-
2021
- 2021-11-15 US US18/036,538 patent/US20230416714A1/en active Pending
- 2021-11-15 MX MX2023005579A patent/MX2023005579A/es unknown
- 2021-11-15 WO PCT/KR2021/016629 patent/WO2022103220A1/ko not_active Ceased
- 2021-11-15 KR KR1020210156862A patent/KR20220065720A/ko active Pending
- 2021-11-15 JP JP2023525997A patent/JP2023549322A/ja active Pending
- 2021-11-15 CA CA3196264A patent/CA3196264A1/en active Pending
- 2021-11-15 EP EP21892387.8A patent/EP4245310A4/en active Pending
- 2021-11-15 AU AU2021377712A patent/AU2021377712A1/en active Pending
- 2021-11-15 IL IL302857A patent/IL302857A/en unknown
- 2021-11-15 CN CN202180075085.8A patent/CN116419759A/zh active Pending
-
2023
- 2023-04-19 ZA ZA2023/04536A patent/ZA202304536B/en unknown
- 2023-05-17 CO CONC2023/0006516A patent/CO2023006516A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021377712A1 (en) | 2023-06-01 |
| AU2021377712A9 (en) | 2024-07-11 |
| CN116419759A (zh) | 2023-07-11 |
| US20230416714A1 (en) | 2023-12-28 |
| CA3196264A1 (en) | 2022-05-19 |
| EP4245310A1 (en) | 2023-09-20 |
| EP4245310A4 (en) | 2024-10-30 |
| IL302857A (en) | 2023-07-01 |
| WO2022103220A1 (ko) | 2022-05-19 |
| MX2023005579A (es) | 2023-05-29 |
| ZA202304536B (en) | 2024-09-25 |
| JP2023549322A (ja) | 2023-11-24 |
| KR20220065720A (ko) | 2022-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021006092A2 (es) | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas | |
| CL2020001857A1 (es) | Conjugado de enzimas terapéuticas. (divisional solicitud 201802045) | |
| CO2021000326A2 (es) | Composiciones y métodos para aumentar o mejorar la transducción de vectores de terapia genética y para eliminar o reducir las inmunoglobulinas | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| EA201592049A1 (ru) | Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения | |
| BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
| PH12020550927A1 (en) | Therapeutic enzyme fusion protein having novel structure and use thereof | |
| MA49727A (fr) | Anticorps et polypeptides dirigés contre cd127 | |
| GT200900248A (es) | "proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpo, que unen especificamente a cd154 y sus usos" | |
| NZ598834A (en) | Prevention, treatment and diagnosis of P. gingivalis infection | |
| ES2184869T3 (es) | Vacuna sub-unitaria contra la infeccion por flavivirus. | |
| BRPI0912570B8 (pt) | anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos | |
| WO2021234160A3 (en) | Ace2-fc fusion proteins and uses thereof | |
| AU2018249796A1 (en) | Antibody Fc variants for improving blood half-life | |
| MX389320B (es) | Anticuerpos anti-tnfrsf25 | |
| EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
| MX2019006444A (es) | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. | |
| MX2020007030A (es) | Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismo. | |
| CL2023003331A1 (es) | Anticuerpos anti-tmprs66 y usos de los mismos. | |
| MX2023004933A (es) | Proteinas de fusion de ace2 y usos de las mismas. | |
| EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение | |
| BR112022017192A2 (pt) | Variantes de transglutaminase | |
| MX2023009921A (es) | Formulaciones de proteinas de fusion ace2-fc. | |
| CO2023006437A2 (es) | Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de enfermedades renales provocadas por o acompañadas de la enfermedad de fabry | |
| UA117493C2 (uk) | Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання |